BioSpace News Archive

Novocure reported financial results for the quarter ended June 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, and Kumquat Biosciences announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

HanAll Biopharma announced that the company had achieved sales of 23.4 billion won, operating profit of 1.6 billion won, and net profit of 3.3 billion won in the second quarter of 2021.

T-Cypher Bio, a rapidly emerging private biotech company pioneering a novel approach to TCR-based therapeutics, announces the formation and members of its Scientific Advisory Board comprising international leaders of T cell immunology.

Calithera Biosciences, Inc., a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s second quarter 2021 financial results will be released on Thursday, August 5, 2021.

Rockwell Medical, Inc. announced that it will host a conference call on Monday, August 16, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and discuss recent business highlights.

Chimerix announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, announced that the company’s CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.

Baudax Bio, Inc. a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.